# Phase 1/2 glioblastoma trials recruiting: 55 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 55 trials in phase 1/2 for glioblastoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 glioblastoma trials: 55 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/glioblastoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 55
- Recruiting or not yet: 55
- Read on: November 19, 2026

## Trials

The 25 newest of 55, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07902037 | A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) | Siren Biotechnology | Phase 1/2 | Not yet recruiting | Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Diffuse Hemispheric Glioma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902037) |
| October 5, 2026 | NCT07859059 | Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma | University of Nebraska | Phase 1/2 | Not yet recruiting | High Grade Glioma, Glioblastoma, Gliosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859059) |
| September 21, 2026 | NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | First Affiliated Hospital of Wenzhou Medical University | Phase 1/2 | Not yet recruiting | Glioblastoma | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831187) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| August 13, 2026 | NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient)... | BreakBio Corp | Phase 1/2 | Not yet recruiting | Glioblastoma (GBM) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762716) |
| August 7, 2026 | NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal... | Jubilant Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM) | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751744) |
| May 22, 2026 | NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma | Myosin Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604285) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| March 30, 2026 | NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | Jecho Biopharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Recurrent Glioblastoma Multiforme(GBM) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501559) |
| March 12, 2026 | NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Mayo Clinic | Phase 1/2 | Recruiting | Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma... | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468136) |
| February 24, 2026 | NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With... | Starlight Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Glioblastoma (GBM) | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431216) |
| February 18, 2026 | NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/2 | Recruiting | Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416188) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| February 6, 2026 | NCT07392957 | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma | Washington University School of Medicine | Phase 1/2 | Recruiting | Glioblastoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392957) |
| February 5, 2026 | NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours | Institute of Cancer Research, United Kingdom | Phase 1/2 | Recruiting | Malignant Primary Gliomas, Glioblastoma Multiforme (GBM) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391215) |
| February 5, 2026 | NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse... | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389278) |
| January 16, 2026 | NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma | Trogenix ltd | Phase 1/2 | Recruiting | Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07346144) |
| September 22, 2025 | NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients | Myosin Therapeutics Inc. | Phase 1/2 | Recruiting | Glioblastoma (GBM) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185880) |
| September 18, 2025 | NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | Not yet recruiting | Glioblastoma of Cerebellum | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180927) |
| August 28, 2025 | NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | Mianyang Central Hospital | Phase 1/2 | Recruiting | Glioblastoma (GBM) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07145047) |
| July 30, 2025 | NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | Guangzhou Virotech Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Glioblastoma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093814) |
| April 13, 2025 | NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours | Filamon LTD | Phase 1/2 | Recruiting | Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer, Glioblastoma Multiforme (GBM), Pancreas Cancer, Skin... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926075) |
| April 6, 2025 | NCT06914128 | A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | Bayer | Phase 1/2 | Recruiting | MTAP-deleted Solid Tumors | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06914128) |
| February 7, 2025 | NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | University of Arizona | Phase 1/2 | Recruiting | Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06814496) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Essen Biotech | 3 |
| Northwell Health | 3 |
| Myosin Therapeutics Inc. | 2 |
| National Cancer Institute (NCI) | 2 |
| Institute of Cancer Research, United Kingdom | 2 |
| [Philogen S.p.A.](https://specstream.ai/data/clinical-trials/company/philogen-s-p-a) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| University of Nebraska | 1 |
| Jubilant Therapeutics Inc. | 1 |
| Haukeland University Hospital | 1 |
| Filamon LTD | 1 |
| SignPath Pharma, Inc. | 1 |
| Université de Sherbrooke | 1 |
| Shenzhen Geno-Immune Medical Institute | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| Neonc Technologies, Inc. | 1 |
| [Debiopharm International SA](https://specstream.ai/data/clinical-trials/company/debiopharm-international-sa) | 1 |
| The Methodist Hospital Research Institute | 1 |
| Advenchen Pharmaceuticals, LLC. | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Universität Münster | 1 |
| Trogenix ltd | 1 |
| University of Arizona | 1 |
| LigaChem Biosciences, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 32 |
| China | 10 |
| United Kingdom | 5 |
| Spain | 4 |
| Switzerland | 3 |
| Australia | 3 |
| Canada | 3 |
| France | 2 |
| South Korea | 2 |
| Denmark | 2 |
| Italy | 2 |
| Singapore | 2 |
| Norway | 1 |
| Germany | 1 |
| Taiwan | 1 |
| Belgium | 1 |
| Czechia | 1 |
| Japan | 1 |
| Netherlands | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Drama schools in the United States](https://specstream.ai/data/businesses/drama-schools/united-states)
- [Sports bars in the United States](https://specstream.ai/data/businesses/sports-bars/united-states)
- [Georgian restaurants in the United States](https://specstream.ai/data/businesses/georgian-restaurants/united-states)
- [Wills, trusts and probate law firms in the United States](https://specstream.ai/data/businesses/wills-trusts-and-probate-law-firms/united-states)
- [Landscaping companies in the United States](https://specstream.ai/data/businesses/landscaping-companies/united-states)
